Monographie - Cyclophosphamide

Letztes “update” :
19/11/2024

Cyclophosphamide

Chemische Struktur

Handelsmarke

Handelsnamen sind als beispielhaft anzusehen. Sonstige Bestandteile können je nach Hersteller oder Land verschieden sein

Alkyloxan	Ägypten, Malaysia
Celomide	Indien
Ciclofosfamida	Argentinien, Chile, Rumänien
Cicloxal	Spanien
Cryofaxol	Mexiko
Cycloblastin	Australien
Cycloblastine	Niederlande
Cyclophosphamid	Dänemark, Deutschland
Cyclophosphamide	Großbritannien, Neuseeland, Saudi-Arabien, Vereinigte Staaten von Amerika
Cyclostin	Deutschland
Cycloxan	Malaysia
Cycram	Ägypten
Cytoxan	Kanada, Ungarn, Vereinigte Staaten von Amerika
Eldamide	Indien
Endoxan	Australien, Belgien, Chile, Deutschland, Ecuador, Frankreich, Griechenland, Indien, Iran, Italien, Kolumbien, Kroatien, Luxemburg, Marokko, Neuseeland, Niederlande, Österreich, Polen, Portugal, Saudi-Arabien, Schweiz, Slowenien, Thailand, Tunesien, Türkei, Ungarn, Venezuela, Vereinigte Arabische Emirate
Endoxana	Großbritannien, Irland
Formitex	Kolumbien, Mexiko
Genoxal	Spanien
Genuxal	Brasilien
Hidrofosmin	Mexiko
Ledoxan	Kolumbien
Ledoxina	Kolumbien, Mexiko
Neophos	Ägypten
Neosar	Vereinigte Staaten von Amerika
Procytox	Kanada
Sendoxan	Dänemark, Finnland, Island, Norwegen, Schweden
Syklofosfamid	Finnland, Türkei

Literaturverzeichnis : Cyclophosphamide

	Typ	Veröffentlichung
3	Zeitung	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
40	Zeitung	Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Kablan J, Cazin M, Cazin JC. Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags. Pharm Sci Communications 1994 ; 4: 97-101.
50	Zeitung	Fleming RA, Olsen DJ, Savage PD, Fox JL. Stability of ondansetron hydrochloride and cyclophosphamide in injectable solutions. Am J Health-Syst Pharm 1995 ; 52: 514-516.
57	Zeitung	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Zeitung	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Zeitung	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Zeitung	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Zeitung	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Zeitung	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
150	Zeitung	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
169	Zeitung	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
170	Zeitung	Brooke D, Scott JA, Bequette RJ. Effect of briefly heating cyclophosphamide solutions. Am J Hosp Pharm 1975 ; 62: 44-45.
172	Zeitung	Beijnen JH, van Gijn R, Challa EE, Kaijser GP, Underberg WJM. Chemical stability of two sterile, parenteral formulations of cyclophosphamide (Endoxan) after reconstitution and dilution in commonly used infusion fluids. J Parenter Sci Technol 1992 ; 46: 111-116.
244	Zeitung	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Zeitung	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Zeitung	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300	Zeitung	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Zeitung	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Zeitung	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
331	Zeitung	Marquardt ED. Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents. Am J Hosp Pharm 1988 ; 45: 2127.
334	Zeitung	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Zeitung	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
491	Zeitung	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Zeitung	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
660	Zeitung	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
905	Zeitung	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Zeitung	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1026	Zeitung	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1410	Zeitung	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Zeitung	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Zeitung	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Zeitung	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1520	Labor	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1625	Zeitung	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Zeitung	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1728	Zeitung	Mittner A, Vincze Z, Jemnitz. Stability of cyclophosphamide containing infusions. Pharmazie 1999 ; 54: 224-225.
1833	Zeitung	Menard C, Bourguignon C, Schlatter J, Vermerie N. Stability of cyclophosphamide and mesna admixtures in polyethylene infusion bags. Ann Pharmacotherapy 2003 ; 37, 12: 1789-1792.
1925	Zeitung	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Zeitung	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Zeitung	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2016	Zeitung	Xu QA, Trissel LA. Compatibility of palonosetron with cyclophosphamide and with ifosfamide during Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 1998-2000.
2104	Zeitung	Iriarte Izura MA, Gozalo garcia MJ, Marcotegui Ros F, Nagore Indurain C, Urdaniz Baztan AO. Estudio de la estabilidad de mezclas ciclofosfamida/mesna e ifosfamida/mesna en soluciones intravenosas de gran volumen. Farm Hosp 2000 ; 24: 145-150
2262	Zeitung	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128	Labor	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3574	Labor	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
4471	Labor	Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019

Mentions Légales